Can we stratify risk to guide therapy

被引:2
|
作者
Alderman, MH [1 ]
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA
关键词
hypertension; treatment; cardiovascular risk; risk stratification;
D O I
10.3109/10641969909060989
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The relation of blood pressure to cardiovascular (CVD) disease is direct, continuous, and independent. Nevertheless, blood pressure alone is a poor predictor of CVD events. In fact, the totality of factors, including smoking, cholesterol, diabetes, target organ damage, and existing cardiovascular disease, together, permit discrimination of persons with similar blood pressure into subgroups with event expectations that might differ by more than twenty-fold. Thus, absolute CVD risk, rather than level of blood pressure, should determine the need for antihypertensive treatment. In addition, conventional treatment, even when effective, prevents only 25% of expected events. Observational study of long term treated patients provides the basis for pre-treatment stratification of CVD risk in patients who will maintain "normal" blood pressure in treatment. This stratification scheme makes it possible to modulate the intensity of therapy to match the potential for CVD prevention. Finally, specific risk factors, influenced by particular antihypertensive therapies, may guide drug selection in individual cases.
引用
收藏
页码:563 / 570
页数:8
相关论文
共 50 条
  • [31] CAN A PROTEOMIC APPROACH RISK STRATIFY THE NEUROGENIC BLADDER IN SPINA BIFIDA PATIENTS?
    Zderic, Stephen
    Weiss, Dana
    Long, Christopher
    Spruce, Lynn
    Ding, Hua
    Roof, Jennifer
    Ischiropoulos, Harry
    Fazelinia, Hossein
    NEUROUROLOGY AND URODYNAMICS, 2023, 42 : S298 - S300
  • [32] AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation
    Chen, I-Hsuan
    Hsu, Chien-Chin
    Yong, Chee-Chien
    Cheng, Yu-Fan
    Wang, Chih-Chi
    Lin, Chih-Che
    Chen, Chao-Long
    CANCERS, 2023, 15 (05)
  • [33] Mammostrat® as a tool to stratify patients at risk of recurrence during endocrine therapy
    Bartlett, J. M. S.
    Thomas, J. S.
    Chetty, U.
    Seitz, R. S.
    Ross, D. T.
    Ring, B. Z.
    Pedersen, H. C.
    Beck, R. A.
    Campbell, F. M.
    Jack, W.
    Kerr, G.
    McKay, L.
    Kunkler, I. H.
    CANCER RESEARCH, 2009, 69 (02) : 212S - 213S
  • [34] Stress echocardiography can risk stratify and prognosticate patients with left ventricular hypertrophy
    Bangalore, Sripal
    Aziz, Emad
    Arshad, Rabia
    Shah, Ajay
    Suryadevara, Ramya Smitha
    Imai, Naohiko
    Parkar, Sanobar
    Cantales, Deborah
    Yao, Siu-Sun
    Chaudhry, Farooq A.
    CIRCULATION, 2006, 114 (18) : 372 - 372
  • [35] Can laboratory blood tests be used to risk stratify patients admitted with pneumonia?
    L Apps
    S Hutchinson
    T Leary
    L Perry
    Critical Care, 18 (Suppl 1):
  • [36] PREDICTORS OF GROWTH RATE FOR RENAL MASSES ON ACTIVE SURVEILLENCE - CAN WE BETTER STRATIFY PATIENT
    Kiziloz, Halil
    Meraney, Anoop
    Dorin, Ryan
    Jackson, Max
    Finnegan, Kyle
    Kesler, Stuart
    Shichman, Steven
    JOURNAL OF UROLOGY, 2013, 189 (04): : E678 - E678
  • [37] Cystoscopic surveillance following nephroureterectomy - can we stratify according to upper tract tumour characteristics?
    Coscione, A.
    Sahu, M.
    Kaul, A.
    Issa, R.
    Perry, M.
    Le Roux, P.
    Ayres, B.
    Anderson, C.
    BJU INTERNATIONAL, 2014, 113 : 38 - 38
  • [38] If we can simulate it, we can insure it: An application to longevity risk management
    Boyer, M. Martin
    Stentoft, Lars
    INSURANCE MATHEMATICS & ECONOMICS, 2013, 52 (01): : 35 - 45
  • [39] Can we customize antithrombotic therapy?
    Puymirat, E.
    Danchin, N.
    ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS, 2019, 11 : S40 - S44
  • [40] Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
    Ellis, R.
    Boggild, M.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (04) : 505 - 508